Panton-Valentine Leukocidin-Positive Staphylococcus aureus Strains Are Associated with Follicular Skin InfectionsDel Giudice P.a · Bes M.b–d · Hubiche T.a · Blanc V.e · Roudière L.a · Lina G.b–d · Vandenesch F.b–d · Etienne J.b–d
aService d’Infectiologie-Dermatologie, Hôpital Bonnet, Fréjus, bCentre National de Référence des Staphylocoques, Université Lyon 1, and cINSERM U851, IFR128, Lyon, dCentre de Biologie Est, Hospices Civils de Lyon, Bron, and eCentre Hospitalier d’Antibes-Juan-les-Pins, Antibes, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: Panton-Valentine leukocidin (PVL)-positive Staphylococcus aureus have been associated with suppurative infections; however, their precise role in skin infections has not been elucidated. We studied the rate of PVL-positive S. aureus in the different types of skin infections and compared follicular to nonfollicular skin infections. Methods: In our institution, patients with a skin infection caused by S. aureus were enrolled in a prospective, observational cohort study (from July 1, 2003 to June 30, 2010). We studied the rate of PVL-positive S. aureus in the different clinical types of skin infections and compared the rate of PVL-positive S. aureus in follicular infections to that in nonfollicular infections. Results: A total 229 skin infections were included: 97 (42.5%) were caused by PVL-positive strains. Thirty-nine of the 53 (74%) follicular infections [8 of the 17 (47%) with folliculitis, 30 of the 35 (85.5%) with furuncles and 1 with a carbuncle (100%)] were caused by PVL-positive S. aureus, compared to 16 of the 131 (12%) nonfollicular infections (p < 0.001). Conclusion: PVL-positive S. aureus strains are mainly associated with follicular skin infections.
© 2011 S. Karger AG, Basel
- Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC: Infectious Diseases Society of America: practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–1406.
- Gravet A, Couppie P, Meunier O, Clyti E, Moreau B, Pradinaud R, Monteil H, Prevost G: Staphylococcus aureus isolated in case of impetigo produce both epidermolysin A or B and LukE-LukD in 78% of 131 retrospective and prospective cases. J Clin Microbiol 2001;39:4349–4356.
- Couppié P, Cribier B, Prevost G: Leukocidin from Staphylococcus aureus and cutaneous infections: an epidemiologic study. Arch Dermatol 1994;130:1208–1209.
- Yamasaki O, Kaneko J, Morizane S, Akiyama H, Arata J, Narita S, Chiba JI, Kamio Y, Iwatsuki K: The association between Staphylococcus aureus strains carrying Panton-Valentine leukocidin genes and the development of deep-seated follicular infection. Clin Infect Dis 2005;40:381–385.
- Lina G, Piemont Y, Godail-Gamot F, et al: Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128–1132.
- Nolte O, Haag H, Zimmerman A, Geiss HK: Staphylococcus aureus positive for Panton-Valentine leukocidin genes but susceptible to methicillin in patients with furuncles. Eur J Clin Microbiol Infect Dis 2005;24:477–479.
- Del Giudice P, Blanc V, De Rougemont A, Hubiche T, Roudière L, Bes M, Lina G, Vandenesch F, Etienne J: Panton-Valentine leukocidin positive Staphylococcusaureus strains cause primary skin abscesses. Dermatology 2009;219:299–302.
- Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA, EMERGEncy ID Net Study Group: Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666–674.
- Cribier B, Prévost G, Couppié P, Finck-Barbançon V, Grosshans E, Piémont Y: Staphylococcus aureus leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992;185:175–180.
- Voyich JM, Otto M, Mathema B, Braugton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, De Leo FR: Is Panton Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006;194:1761–1770.
- Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, De Leo FR: Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus. J Infect Dis 2008;198:1166–1170.
- Tseng CW, Kyme P, Low J, Rocha MA, Alsabeh R, Miller LG, Otto M, Arditi M, Diep BA, Nizet V, Doherty TM, Beenhouwer DO, Liu GY: Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. Plos One 2009;4:e6387.
- Varshney AK, Martinez LR, Hamilton SM, Bryant AE, Levi MH, Gialanella P, Stevens DL, Fries BC: Augmented production of Panton-Valentine leukocidin toxin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus is associated with worse outcome in a murine skin infection model. J Infect Dis 2010;201:62–66.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.